SUO 2017: Identifying The Rate And Risks Of Chronic Kidney Disease Development After Cytoreductive Nephrectomy
Washington, DC (UroToday.com) Cytoreductive nephrectomy has been shown to improve overall survival in patients with metastatic renal cell carcinoma (mRCC). At today’s 2017 SUO winter meeting poster session, Dr. Martin and colleagues presented their research identifying the rate and risks of chronic kidney disease development after cytoreductive nephrectomy.
SUO 2017: Cost Effective Analysis of Neoadjuvant Chemotherapy Prior to Radical Cystectomy in T2 Bladder Cancer
Washington, DC (UroToday.com) Dr. Hamilton and colleagues presented results of their decision analysis for neoadjuvant chemotherapy prior to radical cystectomy (RC) for T2 bladder cancer. Although there is level 1 evidence  and a comprehensive meta-analysis supporting a 5% overall survival benefit for neoadjuvant chemotherapy in bladder cancer , the cost effectiveness of this strategy is still debated. The objective of this study was to present a cost effectiveness analysis of neoadjuvant chemotherapy prior to RC in the setting of T2 bladder cancer.
SUO 2017: A Nationwide Analysis of Complete Urinary Tract Extirpation
Washington, DC (UroToday.com) Dr. Jipp and colleagues assessed a nationwide analysis of complete urinary tract extirpation. Indications for complete urinary tract extirpation (bilateral nephroureterectomy and radical cystectomy) include concomitant upper and lower tract urothelial carcinoma or patients with chronic renal failure and urothelial carcinoma. Given the rarity of this operation, descriptions of complete urinary tract extirpation are limited to case reports and small case series. The objective of this study was to use a population-based database to assess long-term outcomes following complete urinary tract extirpation.
SUO 2017: Hospital Volume and Short-Term Outcomes after Cytoreductive Nephrectomy
Washington, DC (UroToday.com) Dr. Xia and colleagues presented results from their study assessing hospital volume and short-term outcomes after cytoreductive nephrectomy. Indeed, cytoreductive nephrectomy is considered a treatment option for selected patients with metastatic renal cell carcinoma (mRCC), although it can be complex with significant perioperative morbidities. To date, there have been no studies reporting on volume-outcome associations in the CN setting; the current study’s objective was to explore this potential relationship.
SUO 2017: Cytoreductive Nephrectomy In Patients With Metastatic Renal Cell Carcinoma And Tumor Thrombus – Trends And Effect On Overall Survival
Washington, DC (UroToday.com) Dr. Lenis and colleagues presented their population-based research this afternoon at the 2017 SUO annual winter meeting in Washington DC, discussing trends and effect on overall survival for patients undergoing cytoreductive nephrectomy for patients with concomitant tumor thrombus.
SUO 2017: Perioperative Outcomes of Aspirin Use in Partial Nephrectomy
Washington, DC (UroToday.com) Increasing cardiovascular disease has led to increased use of anti-platelet therapy in a patient population who often require urologic surgery. Dr. Ingham and colleagues presented their research assessing perioperative outcomes of aspirin use in partial nephrectomy patients. The objective of the study was to assess perioperative outcomes for those undergoing partial nephrectomy while taking or not taking perioperative aspirin.
SUO 2017: Renal Medullary Carcinoma and Collecting Duct Carcinoma of the Kidney
Washington, DC (UroToday.com) Collecting duct carcinoma and renal medullary carcinoma are rare subtypes of renal cell carcinoma with poor survival. Dr. Beksac and colleagues presented their population-level analysis assessing Renal Medullary Carcinoma and Collecting Duct Carcinoma of the Kidney, a Clinicopathological and Survival Analysis from the National Cancer Database. Indeed, there is no standard way to treat these subtypes in advanced stages. The objective of this study was to characterize the demographic, clinical, pathologic profile and overall survival (OS) of patients diagnosed with collecting duct carcinoma and renal medullary carcinoma of the kidney.